KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Preferred Stock Liabilities (2018 - 2019)

Historic Preferred Stock Liabilities for Vir Biotechnology (VIR) over the last 2 years, with Q3 2019 value amounting to $636.6 million.

  • Vir Biotechnology's Preferred Stock Liabilities rose 10593.2% to $636.6 million in Q3 2019 from the same period last year, while for Sep 2019 it was $636.6 million, marking a year-over-year increase of 10593.2%. This contributed to the annual value of $309.1 million for FY2018, which is 567.88% up from last year.
  • Latest data reveals that Vir Biotechnology reported Preferred Stock Liabilities of $636.6 million as of Q3 2019, which was up 10593.2% from $309.1 million recorded in Q4 2018.
  • Over the past 5 years, Vir Biotechnology's Preferred Stock Liabilities peaked at $636.6 million during Q3 2019, and registered a low of $309.1 million during Q3 2018.